Twist Bioscience

Twist Bioscience Debt

The Debt of Twist Bioscience (TWST) as of Nov 22, 2026 is 94.99 M USD. In the previous year, Debt was 137.32 M USD — a change of -30.83% (lower).

Debt

94.99 MUSD

YoY

-30.83%

Last updated:

In 2026, Twist Bioscience's total debt was 94.99 M USD, a -30.83% change from the 137.32 M USD total debt recorded in the previous year.

The Twist Bioscience Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2019
7.73 M USD
Jan 1, 2020
35.98 M USD
Jan 1, 2021
62.92 M USD
Jan 1, 2022
94.91 M USD
Jan 1, 2023
94.07 M USD
Jan 1, 2024
85.03 M USD
Jan 1, 2025
137.32 M USD
Jan 1, 2026
94.99 M USD
The Twist Bioscience Debt history
YEARDebtYoY
94.99 MUSD-30.83%
137.32 MUSD+61.51%
85.03 MUSD-9.61%
94.07 MUSD-0.89%
94.91 MUSD+50.84%
62.92 MUSD+74.87%
35.98 MUSD+365.30%
7.73 MUSD-97.43%
300.83 MUSD+37.63%
218.59 MUSD+50.13%
145.60 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Twist Bioscience Stock analysis

What does Twist Bioscience do? Twist Bioscience Corp is a company specializing in the production and applications of synthetic DNA. It was founded in 2013 and is based in San Francisco, California, USA. The company utilizes proprietary technologies to cost-effectively produce high-quality and high-quantity synthetic DNA. The company operates in three business areas: DNA synthesis, biopharmaceuticals, and data storage. The DNA synthesis division is the core of the company and involves the production of synthetic DNA for applications in various industries, including medicine, agricultural science, biotechnology, plastic engineering, and others. The company manufactures customized DNA synthesis products tailored to the needs of its customers, allowing them to accelerate and optimize their research and development projects. Twist Bioscience has also developed a proprietary technology called "Twist Biosensor" that enables rapid and cost-effective analysis of genetic variations. The biopharmaceutical division focuses on the development of therapeutics and diagnostics based on synthetic DNA. Twist Bioscience develops antibodies and proteins that can be used in cancer and immunotherapy, as well as diagnostics. In the data storage field, Twist Bioscience develops solutions for storing large amounts of data on DNA. This technology utilizes the dense and stable structure of DNA to securely and reliably store data in the long term. Twist Bioscience's DNA synthesis products are utilized by researchers, companies, and public institutions in various industries. Customers value not only the wide product portfolio but also the high quality and precision of the products, as well as the speed of order processing. The company operates a number of manufacturing facilities near its customers in Europe and Asia to ensure fast and efficient delivery of its products. This allows Twist Bioscience to have a strong position in the global market. In recent years, the company has achieved significant milestones. In 2018, Twist Bioscience went public and raised a total of $70 million through its IPO. The company has also established partnerships with various other companies and institutions to develop new applications and products. Overall, Twist Bioscience is a growing company specializing in the production and applications of synthetic DNA. With its wide range of high-quality and customized DNA synthesis products, as well as its innovative solutions in the biopharmaceutical and data storage sectors, the company has established a strong market position. Twist Bioscience is one of the most popular companies on Eulerpool.

Debt Details

Understanding Twist Bioscience's Debt Structure

Twist Bioscience's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Twist Bioscience's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Twist Bioscience’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Twist Bioscience’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Twist Bioscience stock

Debt of Twist Bioscience is 94.99 M USD in 2026.

Debt of Twist Bioscience changed from 137.32 M USD to 94.99 M USD, representing a -30.83% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Twist Bioscience since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Twist Bioscience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Twist Bioscience

All Key Metrics — Twist Bioscience